section name header

Pronunciation

eye-soe-proe-TER-e-nole

Classifications

Therapeutic Classification: antiarrhythmics, bronchodilators

Pharmacologic Classification: adrenergics

Indications

High Alert


Action

  • Results in the accumulation of cyclic adenosine monophosphate (cAMP) at beta-adrenergic receptors.
  • Produces bronchodilation.
  • Produces positive inotropic and chronotropic effects.
Therapeutic effects:
  • Bronchodilation.
  • Increased heart rate.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Metabolism occurs in the lung, liver, and other tissues; 50% excreted unchanged by the kidneys.

Half-Life: 2.5–5 min.

Time/Action Profile

(bronchodilation)

ROUTEONSETPEAKDURATION
IVimmediateunknown<1 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: angina, hypertension, tachycardia, ARRHYTHMIAS

Endo: hyperglycemia

GI: nausea, vomiting, xerostomia

Neuro: nervousness, restlessness, tremor, headache, insomnia

Misc: pink/red discoloration of saliva

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Isuprel